ATX-001
/ Aclaris
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 03, 2025
Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138.
(PubMed, J Pharmacol Exp Ther)
- "ATI-2138 inhibits JAK3 and ITK in enzyme and functional cellular assays, demonstrates disease-modifying activity in rodent models of arthritis and colitis, and inhibits biomarkers linked to both ITK and JAK3 activity in healthy human participants. With this dual kinase activity against components of these inflammatory signaling pathway, ATI-2138 has the potential for enhanced therapeutic efficacy in the treatment of autoimmune and chronic inflammatory disease."
Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Rheumatology • IL2 • ITK • JAK3
1 to 1
Of
1
Go to page
1